Humana (NYSE:HUM) Releases FY 2025 Earnings Guidance

Humana (NYSE:HUM - Get Free Report) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 16.250-16.250 for the period, compared to the consensus estimate of 16.350. The company issued revenue guidance of -.

Humana Stock Down 0.9%

Shares of NYSE:HUM traded down $2.18 during mid-day trading on Thursday, hitting $228.65. 765,598 shares of the company traded hands, compared to its average volume of 1,772,886. Humana has a 12-month low of $212.45 and a 12-month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The stock has a 50-day moving average price of $254.92 and a two-hundred day moving average price of $265.74. The stock has a market cap of $27.60 billion, a P/E ratio of 22.96, a P/E/G ratio of 2.05 and a beta of 0.49.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $7.23 EPS. On average, equities research analysts forecast that Humana will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.55%. Humana's dividend payout ratio is currently 25.04%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HUM. Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Morgan Stanley dropped their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 12th. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. JPMorgan Chase & Co. dropped their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Sixteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $284.48.

Institutional Trading of Humana

A hedge fund recently bought a new stake in Humana stock. Revolve Wealth Partners LLC acquired a new stake in shares of Humana Inc. (NYSE:HUM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 798 shares of the insurance provider's stock, valued at approximately $202,000. Institutional investors own 92.38% of the company's stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.